Milestone Pharmaceuticals
MIST
78 hedge funds and large institutions have $66.4M invested in Milestone Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 23 increasing their positions, 23 reducing their positions, and 13 closing their positions.
41% more capital invested
Capital invested by funds: $47.2M → $66.4M (+$19.2M)
6.21% more ownership
Funds ownership: 33.59% → 39.8% (+6.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 23
10% less funds holding
Funds holding: 87 → 78 (-9)
14% less call options, than puts
Call options by funds: $289K | Put options by funds: $337K
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.91M |
| 2 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$5.29M |
| 3 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$2.95M |
| 4 |
Millennium Management
New York
|
+$2.55M |
| 5 |
RI
RTW Investments
New York
|
+$2.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.38M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.01M |
| 3 |
Two Sigma Investments
New York
|
-$443K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$262K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$254K |
MIST Hedge Fund Activity: Q2 2026 in Review
78 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q2 2026, worth a combined $66.4M — up 41% from $47.2M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of MIST and 6 opened new positions — a net loss of 7 holders — while 23 trimmed existing stakes and 23 added.
The largest buyer was Point72 Asset Management, adding an estimated $6.91M. The largest seller was Goldman Sachs, exiting entirely with an estimated $2.38M sold.
- 78 institutional investors held Milestone Pharmaceuticals (MIST) as of Q2 2026, down from 87 in Q1 2026.
- Funds reported $66.4M of Milestone Pharmaceuticals stock for Q2 2026, up 41% quarter-over-quarter.
- 6 funds opened new Milestone Pharmaceuticals positions in Q2 2026 and 13 closed out, a net change of -7 holders.
- The largest Milestone Pharmaceuticals buyer in Q2 2026 was Point72 Asset Management, an estimated $6.91M added.
- The largest Milestone Pharmaceuticals seller in Q2 2026 was Goldman Sachs, an estimated $2.38M sold.
Based on aggregated 13F filings for Q2 2026.